Novartis MS Drug Mayzent Gets Europe OK

Boost For Neuroscience Portfolio

Mayzent is the first oral treatment specifically indicated for patients with secondary-progressive multiple sclerosis and while it is expected to be a blockbuster, the company tells Scrip that educational programs for physicians are a priority.

Sea_Euro_Flag
Europe waves Mayzent through • Source: Shutterstock

Novartis AG's neuroscience franchise has been strengthened further with the company getting the green light from the European Commission to market Mayzent for the treatment of adults with secondary progressive multiple sclerosis (SPMS) with active disease.

The approval, which follows a positive opinion in November from the European Medicines Agency’s drug evaluation committee, the CHMP, was...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Neurological

More from Therapy Areas